Literature DB >> 7459891

PLasma half-life and urinary excretion of cyclophosphamide in children.

N E Sladek, J Priest, D Doeden, C J Mirocha, S Pathre, W Krivit.   

Abstract

The plasma half-life and urinary excretion of cyclophosphamide were determined in 13 children who had various malignancies and/or who were being prepared for bone marrow transplantation. Disappearance from the plasma following iv infusion over a 1-2 hour period was first-order. Urinary excretion was maximal during the first 8 hours after administration and was essentially complete in 24 hours. The plasma half-life in children not receiving known inducers of hepatic microsomal mixed-function oxygenase activity or cyclophosphamide in the 3-week period prior to each determination ranged from 145 to 390 minutes. These values are lower than those ordinarily found in adult patients. The fraction of the total dose excreted in the urine as the parent compound ranged from 4% to 27%. Repeated administration of cyclophosphamide at approximately 30-60 day intervals did not appear to alter its plasma half-life but did appear to increase its urinary excretion. Daily administration of cyclophosphamide (approximately 50 mg/kg/day x 2 or 4) significantly decreased its plasma half-life and urinary excretion suggesting that it may reversibly induce its own metabolism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7459891

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

1.  A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients.

Authors:  M Hassan; U S Svensson; P Ljungman; B Björkstrand; H Olsson; M Bielenstein; M Abdel-Rehim; C Nilsson; M Johansson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 2.  Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors:  F M Balis
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

3.  Repeated high-dose cyclophosphamide administration in bone marrow transplantation: exposure to activated metabolites.

Authors:  U Schuler; G Ehninger; T Wagner
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Pharmacokinetics of cyclophosphamide in Kenyan African children with lymphoma.

Authors:  F D Juma; D K Koech; E G Kasili; T Ogada
Journal:  Br J Clin Pharmacol       Date:  1984-07       Impact factor: 4.335

5.  Effect of body weight on the pharmacokinetics of cyclophosphamide in breast cancer patients.

Authors:  G Powis; P Reece; D L Ahmann; J N Ingle
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Pharmacokinetic study of indicine N-oxide in pediatric cancer patients.

Authors:  M M Ames; J S Miser; W A Smithson; P F Coccia; C S Hughes; D M Davis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

8.  Pharmacokinetics and metabolism of cyclophosphamide administered after total body irradiation of bone marrow transplant recipients.

Authors:  U Schuler; P Waidelich; H Kolb; T Wagner; G Ehninger
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

9.  Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook.

Authors:  Udo Vester; Birgitta Kranz; Stephanie Zimmermann; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2003-05-16       Impact factor: 3.714

10.  Pharmacokinetics of melphalan in children following high-dose intravenous injection.

Authors:  I A Taha; R A Ahmad; D W Rogers; J Pritchard; H J Rogers
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.